Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 11/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SPR | P35270 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4602724 | 0.92 | KMT2A (0.47) | MEN1NPC1USP2RAB9AKMT2A | |
| SCHEMBL4602444 | 0.90 | TDO2 (0.48) | GPR84HTR2A | |
| SCHEMBL4601800 | 0.82 | TDO2 (0.50) | GPR84HTR2A | |
| SCHEMBL27788547 | 0.81 | MPO (0.52) | MEN1NPC1USP2RAB9AKMT2A | |
| SCHEMBL4604316 | 0.80 | CYP2A6 (0.47) | MEN1NPC1USP2RAB9AKMT2A | |
| SCHEMBL27640766 | 0.79 | MPO (0.56) | MEN1NPC1USP2RAB9AKMT2A | |
| SCHEMBL3741787 | 0.73 | KMT2A (0.56) | MEN1NPC1USP2RAB9AKMT2A | |
| SCHEMBL25884870 | 0.73 | MPO (0.65) | KMT2AGPR84MPOHTR2ASLC6A4 | |
| SCHEMBL13957453 | 0.71 | CAPN1 (0.56) | MEN1NPC1USP2RAB9AKMT2A | |
| SCHEMBL4603999 | 0.71 | CYP2A6 (0.50) | MEN1NPC1USP2RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242662-A1 | Organic Compounds | NIHONYANAGI ATSUKO | 2008-10-02 | — | — | US | claimed |
| EP-1915366-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | Novartis AG (CH) | 2008-04-30 | — | — | EP | claimed |
| WO-2006128659-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS. | NOVARTIS AG (CH) | 2006-12-07 | — | — | WO | claimed |
| US-20080242662-A1 | Organic Compounds | NIHONYANAGI ATSUKO | 2008-10-02 | — | — | US | disclosed |
| EP-1915366-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | Novartis AG (CH) | 2008-04-30 | — | — | EP | disclosed |
| WO-2006128659-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS. | NOVARTIS AG (CH) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242662-A1 | Organic Compounds | REN, ACE, ECE1 | MEN1 1740/4885NPC1 1447/4885USP2 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.